Acute Coronary Syndrome Clinical Trial
Official title:
Oxidized LDL, Oxidized LDL Receptor 1 (OLR1) Gene Polymorphism With Oxygen Therapy in Acute Myocardial Infarction.
Coronary artery disease (CAD) is increasing rapidly in Egyptian people and manifesting a younger age. Higher plasma low-density lipoprotein cholesterol (LDL-C), is a major predictor for the development of CAD. However, whether oxidized-LDL (ox-LDL) can be used as a risk factor for myocardial infarction (MI) has not been fully investigated. Therefore, the aim of the present study was to examine the role of ox-LDL as a risk factor for the presence and clinical outcomes in patients with MI.
Cardiovascular disease, which is multifactorial and caused by complex interactions of genetic
and environmental factors, represents the main cause of death all over the world. Traditional
risk factors for coronary atherosclerosis include age, smoking, male gender, hypertension and
diabetes. Newly defined risk factors such as hyper-homocysteine, elevated plasma levels of
OxLDL and oxidative stress are also emerging.
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the major receptor of
oxidized low-density lipoproteins which regulates the growth of a variety of cells and is
important in inflammation, atherosclerosis, oxidative stress, and tissue remodeling. LOX-1 is
expressed in various cells, including endothelial cells, macrophages, and chondrocytes, and
its expression is enhanced by proinflammatory cytokines. The LOX1 gene, also known as OLR1,
is located on the chromosome 12p13.1-p12.3. The LOX1 protein is synthesized as a 40-kDa
precursor protein and is composed of four domains: an extracellular lectin-like domain at the
C-terminal, a connecting neck domain, a transmembrane domain, and an N-terminal cytoplasmic
domain. Three single nucleotide polymorphism (SNPs), namely, intron 4 (G→A), intron 5(T→G),
and 3' UTR (T→C) in the LOX1 gene, have been previously reported. These polymorphisms have
also been associated with CAD.
Oxygen is a lifesaving drug. Giving oxygen to a patient with an impending clinical emergency
has become knee‑jerk reflex reaction of the clinician. Patient with AMI has compromised
myocardial perfusion and event arises due to myocardial hypoxia. It appears quite logical and
biologically plausible to give oxygen in such situations to improve the oxygenation of the
ischemic myocardial tissue and decrease ischemic pain. On the other side, oxygen may be
harmful with a mechanism such as the paradoxical effect of oxygen in decreasing coronary
artery blood flow and increasing coronary vascular resistance due to increased oxygen free
radicals. The investigators aimed to examine the association of the OLR1 gene with AMI or CAD
in a novel, well-phenotyped, and homogenous, population and its correlation with oxygen
therapy in these patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013813 -
Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI
|
N/A | |
Recruiting |
NCT05846893 -
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
|
N/A | |
Recruiting |
NCT05412927 -
AngelMed Guardian® System PMA Post Approval Study
|
||
Completed |
NCT02750579 -
Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?
|
N/A | |
Completed |
NCT04102410 -
Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients
|
N/A | |
Enrolling by invitation |
NCT03342131 -
Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome
|
N/A | |
Recruiting |
NCT01218776 -
International Survey of Acute Coronary Syndromes in Transitional Countries
|
||
Enrolling by invitation |
NCT04676100 -
International CR Registry
|
||
Completed |
NCT03590535 -
5th Generation cTnT in ED ACS
|
||
Recruiting |
NCT05437900 -
INSIGHTFUL-FFR Clinical Trial
|
Phase 4 | |
Completed |
NCT05551429 -
Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
|
||
Terminated |
NCT04316481 -
IDE-ALERTS Continued Access Study
|
N/A | |
Active, not recruiting |
NCT04475380 -
Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
|
||
Not yet recruiting |
NCT04852146 -
Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
|
||
Active, not recruiting |
NCT02892903 -
In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?
|
N/A | |
Completed |
NCT04077229 -
Piloting Text Messages to Promote Positive Affect and Physical Activity
|
N/A | |
Completed |
NCT02944123 -
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
|
Phase 3 | |
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Active, not recruiting |
NCT02922140 -
The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit
|
N/A | |
Completed |
NCT02673437 -
Rivaroxaban ACS Specialist Cohort Event Monitoring Study
|